EMERGENT HEALTH CORP - EMGE STOCK NEWS

Emergent Health Corp. (OTC Pink:EMGE) announced a new initiative where CEO Jim Morrison will provide monthly updates on the company's progress and growth strategies. Highlighting ambition and creativity, Morrison aims to enhance shareholder value through transparency. The company recently introduced the 'MAXIMUS Men's Health' vertical focused on regenerative health solutions. Emergent Health specializes in innovative products in the regenerative health sector, distributing through e-commerce and influencer marketing. Despite positive strides, the press release includes a Safe Harbor Statement outlining potential risks and uncertainties affecting future performance.

Emergent Health Corp. (OTC Pink: EMGE) has announced its revenue forecast of $16 million for 2023, driven by recent acquisitions and increasing current revenues. The company is launching a new initiative, MAXIMUS Men's Health, focused on regenerative health products targeting men's health issues, leveraging its successful PRP (Platelet-Rich Plasma) treatments. Former L'Oréal president and current CEO, Jim Morrison, stated that the brand seeks to meet the needs of modern male patients addressing aging challenges. Emergent plans to provide updates on its growth strategy in the coming weeks.

Emergent Health Corp. (EMGE) announced the acquisition of Nanosthetic Cosmetic Labs, effective March 1, 2023. This strategic acquisition is expected to contribute $3.5 million in revenue for 2023. By integrating Nanosthetic's proprietary technology with its subsidiary, Evolutionary Biologics, Emergent aims to develop groundbreaking cosmetic products compliant with FDA regulations. Former L'Oréal President Jim Morrison emphasized the transformative potential of this acquisition, which will enhance cost efficiencies. Nanosthetic has focused on R&D for a novel cosmetic product not previously available in the market, projecting a strong market introduction.

Emergent Health Corp. (OTC PiNK:EMGE) announced the execution of a Letter of Intent to acquire a profitable company in the regenerative medical field, which currently reports revenues of $5.4 million and projects $9 million for 2023. The target company boasts over 300 sales representatives across the U.S. and has developed the largest Osteoarthritis Treatment Network in the country. CEO Jim Morrison emphasized the strategic compatibility of the businesses and expects the acquisition to enhance revenue and profit, while also creating synergy among 400 field sales reps. The merger is projected to finalize within 60 to 90 days.

Emergent Health Corp. (OTC Pink: EMGE) announced potential acquisition talks with a profitable company in the Medical Field specializing in osteoarthritis treatment and P.R.P. products. The target has established America's largest Osteoarthritis Treatment Network and possesses a broad portfolio of intellectual property. CEO Jim Morrison expressed confidence in the acquisition, citing significant synergy and an expected revenue/profit doubling in 2023. Additionally, Emergent plans to provide a financial forecast soon to outline aggressive expansion strategies, alongside updates on acquiring Nanosthetic Corp.

Emergent Health Corp. (EMGE) has appointed Charlie McMenamin, former Director of National Accounts at Kraft Foods, to its Board of Directors, focusing on product placement across major retail companies. With 25 years of experience in consumer products, McMenamin has a proven track record of leading sales organizations generating $7 million to $12 billion annually. CEO Jim Morrison highlighted McMenamin's unmatched knowledge in retail distribution as crucial for the company’s growth and upcoming product rollout. Emergent specializes in products within the Regenerative Health space, distributing both ingestibles and topicals.

Emergent Health Corp. (EMGE) projects $3.5 million in revenues for fiscal year 2023, supported by the upcoming acquisition of Nanosthetic Corp.. This acquisition is expected to close before February's end and will enhance the capabilities of Emergent's subsidiary, Evolutionary Biologics. Nanosthetic will manufacture regenerative health products in a controlled cleanroom environment once FDA clearance is obtained. CEO Jim Morrison highlights the strategic importance of this acquisition, which aims to reduce the cost of goods by over 50% and eliminate the need for outsourcing. This integration will create a vertically integrated biologics company, expanding Emergent's product offerings.

Emergent Health Corp. (OTC PINK:EMGE) announced the appointment of Charlie McMenamin, a seasoned veteran in consumer products with 25 years of experience, to its Board of Directors. Formerly with Kraft Foods, McMenamin has a proven track record in driving sales for major brands. His expertise spans several sectors, including CPG, IT, and biotech. CEO Jim Morrison expressed confidence that McMenamin’s leadership will enhance Emergent's growth and product rollout. The company specializes in Regenerative Health products, leveraging online distribution and influencer marketing strategies. Emergent's subsidiaries focus on pet wellness and plant-based products.

Emergent Health Corp. (OTC PINK:EMGE) announced a Letter of Intent to acquire Nanosthetic Corp., a biologics company, to enhance its product offerings in the regenerative health sector. The acquisition aims to establish a Cleanroom for FDA-approved clinical trials and pharmaceutical-grade product manufacturing. Nanosthetic's innovative sterile processing techniques promise endotoxin-free products. CEO Jim Morrison emphasized the synergy between the companies, projecting an increase in revenue for Emergent's Evolutionary Biologics division. The deal is contingent upon due diligence and securing funding for necessary equipment.